In the collaboration, compounds developed by Sprint Bioscience in its MASH programme will be evaluated by EDDC, Singapore’s national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR), in inflammatory disease models to assess their broader anti-inflammatory effects. After the evaluation, EDDC will have the option to take over and further develop the program. Any future revenues will be shared between Sprint Bioscience and EDDC based on the investment each party has made in the programme.

“our programme is attracting interest in inflammatory conditions as well, and excited at the potential to help patients with various inflammatory and autoimmune diseases. Given Sprint Bioscience’s focus on oncology, we see this collaboration as an excellent opportunity to gain access to the expertise required to evaluate these opportunities, thereby maximising the value of the programme,” said Johan Emilsson, CEO of Sprint Bioscience.

“EDDC looks forward to collaborating with Sprint Bioscience to expand our portfolio in inflammation and immunology. This partnership builds on a strong foundation of scientific groundwork that has already been done in this programme, and we are excited to explore its potential to provide meaningful solutions for patients living with debillitating inflammatory and autoimmune diseases,” said Prof Damian O’Connell, CEO of EDDC